Market Closed -
Nasdaq
04:30:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
4.03
USD
|
-12.96%
|
|
-14.62%
|
-23.09%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
147.4
|
56.7
|
99.94
|
275.4
|
245.7
|
-
|
-
|
Enterprise Value (EV)
1 |
147.4
|
56.7
|
99.94
|
275.4
|
245.7
|
245.7
|
245.7
|
P/E ratio
|
-4.4
x
|
-1.3
x
|
-1.72
x
|
-4.16
x
|
-3.13
x
|
-3.34
x
|
-3.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
199
x
|
73.3
x
|
177
x
|
157
x
|
366
x
|
19.8
x
|
EV / Revenue
|
-
|
199
x
|
73.3
x
|
177
x
|
157
x
|
366
x
|
19.8
x
|
EV / EBITDA
|
-6.66
x
|
-1.33
x
|
-1.85
x
|
-
|
-2.68
x
|
-2.65
x
|
-
|
EV / FCF
|
-6.43
x
|
-
|
-2.29
x
|
-4.28
x
|
-2.57
x
|
-2.52
x
|
-2.75
x
|
FCF Yield
|
-15.6%
|
-
|
-43.6%
|
-23.4%
|
-39%
|
-39.6%
|
-36.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
12,927
|
13,005
|
31,827
|
52,563
|
60,965
|
-
|
-
|
Reference price
2 |
11.40
|
4.360
|
3.140
|
5.240
|
4.030
|
4.030
|
4.030
|
Announcement Date
|
3/9/21
|
3/9/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.285
|
1.363
|
1.558
|
1.567
|
0.6722
|
12.42
|
EBITDA
1 |
-
|
-22.11
|
-42.61
|
-53.92
|
-
|
-91.51
|
-92.76
|
-
|
EBIT
1 |
-
|
-22.21
|
-43.62
|
-54.99
|
-67.12
|
-93.95
|
-94.59
|
-97.33
|
Operating Margin
|
-
|
-
|
-15,303.51%
|
-4,034.48%
|
-4,308.09%
|
-5,995.42%
|
-14,072.31%
|
-783.79%
|
Earnings before Tax (EBT)
1 |
-
|
-22.13
|
-43.51
|
-55.26
|
-62.62
|
-90.57
|
-96.11
|
-94.37
|
Net income
1 |
-
|
-22.13
|
-43.51
|
-55.28
|
-62.68
|
-90.67
|
-96.11
|
-94.37
|
Net margin
|
-
|
-
|
-15,267.72%
|
-4,055.61%
|
-4,023.11%
|
-5,785.93%
|
-14,298.99%
|
-759.98%
|
EPS
2 |
-2.370
|
-2.590
|
-3.350
|
-1.830
|
-1.260
|
-1.288
|
-1.205
|
-1.073
|
Free Cash Flow
1 |
-
|
-22.92
|
-
|
-43.55
|
-64.35
|
-95.71
|
-97.34
|
-89.24
|
FCF margin
|
-
|
-
|
-
|
-3,195.08%
|
-4,130.36%
|
-6,108.07%
|
-14,481.85%
|
-718.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/9/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.271
|
5.367
|
0.407
|
0.359
|
0.011
|
0.41
|
0.458
|
0.544
|
0.146
|
0.532
|
0.3552
|
0.3557
|
0.33
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-14.55
|
-13.62
|
-
|
-
|
-
|
-
|
-
|
-20.4
|
-22.6
|
-23
|
-
|
-
|
EBIT
1 |
-13.64
|
-7.026
|
-14.52
|
-14.83
|
-13.84
|
-17.31
|
-16.5
|
-16.83
|
-16.48
|
-23.52
|
-23.36
|
-23.56
|
-23.73
|
-24.2
|
-24.6
|
Operating Margin
|
-5,032.47%
|
-130.91%
|
-3,567.08%
|
-4,129.81%
|
-125,809.09%
|
-4,222.68%
|
-3,603.28%
|
-3,093.2%
|
-11,285.62%
|
-4,421.8%
|
-6,577.74%
|
-6,623.37%
|
-7,190%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.62
|
-7.012
|
-14.48
|
-14.77
|
-14.22
|
-16.24
|
-15.61
|
-15.64
|
-15.14
|
-22.44
|
-22.53
|
-23.06
|
-23.03
|
-24.2
|
-24.6
|
Net income
1 |
-13.62
|
-7.012
|
-14.48
|
-14.77
|
-14.24
|
-16.26
|
-15.62
|
-15.65
|
-15.16
|
-22.45
|
-22.59
|
-22.79
|
-23.04
|
-24.2
|
-24.6
|
Net margin
|
-5,024.72%
|
-130.65%
|
-3,558.72%
|
-4,113.09%
|
-129,409.09%
|
-3,964.63%
|
-3,410.04%
|
-2,877.02%
|
-10,380.82%
|
-4,220.3%
|
-6,360.05%
|
-6,406.97%
|
-6,981.92%
|
-
|
-
|
EPS
2 |
-1.050
|
-0.5400
|
-0.4300
|
-0.4000
|
-0.3600
|
-0.4400
|
-0.3600
|
-0.2700
|
-0.1900
|
-0.3500
|
-0.3200
|
-0.3150
|
-0.3133
|
-0.3000
|
-0.2950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/29/23
|
5/12/23
|
8/8/23
|
11/7/23
|
3/21/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-22.9
|
-
|
-43.5
|
-64.4
|
-95.7
|
-97.3
|
-89.2
|
ROE (net income / shareholders' equity)
|
-
|
-54.1%
|
-80%
|
-96.1%
|
-73.7%
|
-120%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-2.460
|
-1.990
|
-1.430
|
-1.270
|
-1.330
|
-1.410
|
-
|
Capex
1 |
-
|
1.78
|
3.39
|
0.16
|
1.05
|
1.45
|
0.8
|
0.83
|
Capex / Sales
|
-
|
-
|
1,187.72%
|
12.03%
|
67.2%
|
92.34%
|
119.12%
|
6.72%
|
Announcement Date
|
3/6/20
|
3/9/21
|
3/9/22
|
3/29/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
4.03
USD Average target price
11.6
USD Spread / Average Target +187.84% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.09% | 246M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|